Clinical Trials Logo
  1. Home
  2. Myeloid Malignancy
  3. NCT03850418

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Myeloid Malignancy Clinical Trial

Official title:
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Clinical Trial Summary

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03850418
Study type Interventional
Source Henry Ford Health System
Contact shatha farhan, MD
Phone 313 916 5002
Email SFARHAN1@HFHS.ORG
Status Recruiting
Phase Phase 2
Start date July 1, 2019
Completion date February 20, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04501120 - Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML Phase 1/Phase 2
Not yet recruiting NCT06090513 - Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients
Recruiting NCT05579769 - A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies Phase 2
Recruiting NCT05583175 - Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies Phase 2
Terminated NCT01596699 - Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Phase 2
Recruiting NCT04906031 - Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations Phase 2
Recruiting NCT05455294 - Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Phase 1
Recruiting NCT02958462 - Pre-myeloid Cancer and Bone Marrow Failure Clinic Study N/A
Recruiting NCT03855371 - Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS Phase 1
Recruiting NCT05841771 - Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. Phase 2
Completed NCT04214860 - APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies Phase 1
Active, not recruiting NCT05350163 - T-cell Receptor α/β Depleted Donor Lymphocyte Infusion Phase 1
Not yet recruiting NCT06378437 - A Study of GLB-001 in Patients With Myeloid Malignancies Phase 1
Not yet recruiting NCT05875805 - A Telehealth Advance Care Planning Intervention N/A
Not yet recruiting NCT06129734 - Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant Phase 1/Phase 2